Sarepta Therapeutics (SRPT)
$85.77
1.67 (1.91%)
SRPT Stock Quote Delayed 15 Minutes
Previous Close
$85.77
Market Cap
5.62B
PE Ratio
-29.17
EPS
-2.94
Volume (Avg. Vol.)
809,306
Day's Range
85.70 - 88.40
52-Week Range
72.05 - 158.80
Dividend & Yield
N/A (N/A)
SRPT Stock Predictions, Articles, and Sarepta Therapeutics News
5 Top Stock Trades for Tuesday: AAPL, GM, SRPT
Apple, General Motors, Delta Air Lines, Sarepta and Bristol-Myers Squibb were our top stock trades to watch for Tuesday. Here's what you need to know.
Stock Market Today: Beyond Meat Makes a Friend on Wall Street
Apple's health initiative can't keep key people and Sarepta Therapeutics' CLR are a couple more top news items about the stock market today.
Nasdaq Today: Apple Loses Ive and the Nasdaq’s Q3 Outlook
The second quarter is the books, at least as far as the stock market is concerned. Here's a look at the Nasdaq today.
5 Top Stock Trades for Monday: STZ, C, UBER
STZ beat on earnings, and the Fed approved higher dividends and buybacks for the bank stocks. Here are the top stock trades heading into next week.
7 Stocks to Buy for Over 20% Upside Potential
If you’re looking for a quick portfolio boost, look no further. Here are 7 stocks to buy with tons of upside according to top analysts.
Why Sarepta Therapeutics (SRPT) Stock Is Sinking Today
Sarepta Therapeutics (SRPT) stock is sinking after the company's late Tuesday announcement that it was offering a $350 million stock ofering.
Why NOW Is the Time to Buy Gene Therapy Stocks
Over the long term, gene therapy stocks will head higher and the last few weeks' of headlines show investors why.
Why Sarepta Therapeutics Stock Is Starting to Shine Again
SRPT stock rebounded nicely from its sub-$100 low last month. More upside is possible as the Sarepta ramps up an important study.
Time to Take Some Profits in Sarepta Therapeutics Stock
Sarepta used the lobbying of patient families to win approval of a drug that may not work against Duchenne muscular dystrophy. It may be time to take profits in SRPT stock..
7 Strong Buy Stocks Analysts Are Upgrading Now, Including Facebook, Inc.
Here we dig down into seven intriguing stock rating upgrades from the Street. Why now? Why are analysts turning bullish on these stocks? All seven of these stocks share a 'Strong Buy' analyst consensus rating from the Street. The result: you can be confident that these stocks are the crème de la crème.
Why Sarepta Therapeutics Inc Stock is Sliding Today
Sarepta Therapeutics (SRPT) stock was hit hard on Friday after reports claim one of its studies was put on hold due to an adverse event.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
D
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!
